Alnylam Pharmaceuticals (alny 1 09/15/27)
13F holders, Q2 2025 (June 30)6holders −1
1new positions
2sold out
$1.30avg. 13F price*
At the end of Q2 2025, 6 institutions reported holding Alnylam Pharmaceuticals (alny 1 09/15/27) in their 13F filings, down 1 from Q1 2025. 1 opened new positions and 2 sold out. The largest holders were BNP PARIBAS ASSET MANAGEMENT Holding S.A. ($6.4M), State of Wisconsin Investment Board ($2.6M) and Bank of New York Mellon Corp ($2.2M).
- Company
- Alnylam Pharmaceuticals (alny 1 09/15/27)
- CUSIP
- 02043QAB3
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q1 2025 → Q2 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 1 | $2.6M |
| Exits | 2 | $573K |
All 13F filers, Q1 2025 → Q2 2025: 2,702,000 shares bought and 2,122 shares sold, net +2,699,878 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 6 holders
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.02% | No change | 4,950,000 | $6.4M |
| State of Wisconsin Investment Board | 0.01% | New | 2,000,000 | $2.6M |
| Bank of New York Mellon Corp | 0.00% | Add +70.0% | 1,700,000 | $2.2M |
| Sei Investments Co. | 0.00% | No change | 251,000 | $326K |
| Oppenheimer Asset Management Inc. | 0.00% | No change | 79,000 | $103K |
| Stephens Inc. | 0.00% | Add +9.1% | 24,000 | $31K |
"% of holder's portfolio" is ALNYLAM PHARMACEUTICALS (ALNY 1 09/15/27)'s weight in each manager's 13F, not the share of Alnylam Pharmaceuticals (alny 1 09/15/27) the manager owns.